Drew Moghanaki: All patients getting CRT for locally advanced NSCLC must undergo EGFR testing

Drew Moghanaki shared on X/Twitter:

”This presentation by Suresh S. Ramalingam marks a historical moment when workflows for radiation oncologists change worldwide. From this day forward, all patients getting CRT for locally advanced NSCLC must undergo EGFR testing.

A hazard ratio of 0.16 is simply outstanding, justifying the standing ovation for the study participants and research team.

The majority of AEs were Grade 1/2.

I agree, the standard of care has now changed.

Here’s the same-day publication if you want to read more into the details.”

Source: Drew Moghanaki/X

Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).